X0306 4 2018-09-17 0 0001492422 Apellis Pharmaceuticals, Inc. APLS 0001543112 Morningside Venture Investments Ltd 2ND FLOOR, LE PRINCE DE GALLES 3-5 AVENUE DES CITRONNIERS MC 98000 O9 MONACO 0 0 1 0 Common Stock 2018-09-17 4 P 0 31400 18.50 A 11384703 D Common Stock 2018-09-17 4 P 0 8600 18.84 A 11393303 D Common Stock 2018-09-18 4 P 0 40000 18.47 A 11433303 D Common Stock 2018-09-19 4 P 0 60000 18.09 A 11493303 D The reported price is a weighted average price. These shares were purchased on 9/17/2018 in multiple transactions at prices ranging from $17.75 to $18.74, inclusive. The reporting person undertakes to provide to Apellis Pharmaceuticals, Inc., any security holder of Apellis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price is a weighted average price. These shares were purchased on 9/17/2018 in multiple transactions at prices ranging from $18.75 to $18.99, inclusive. The reporting person undertakes to provide to Apellis Pharmaceuticals, Inc., any security holder of Apellis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price is a weighted average price. These shares were purchased on 9/18/2018 in multiple transactions at prices ranging from $18.23 to $18.96, inclusive. The reporting person undertakes to provide to Apellis Pharmaceuticals, Inc., any security holder of Apellis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price is a weighted average price. These shares were purchased on 9/19/2018 in multiple transactions at prices ranging from $17.81 to $18.44, inclusive. The reporting person undertakes to provide to Apellis Pharmaceuticals, Inc., any security holder of Apellis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Louise Mary Garbarino, Jill Marie Franklin, Peter Stuart Allenby Edwards and Raymond Long Sing Tang, the directors of Morningside Venture Investments, Ltd. ("MVIL"), share voting and dispositive control over the shares held by MVIL. /s/ Louise Mary Garbarino 2018-09-19 /s/ Jill Marie Franklin 2018-09-19